Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 28, 2018

Novo Nordisk reports positive results from SUSTAIN 6 trial

Novo Nordisk has reported positive results from the SUSTAIN 6 trial, a Phase llla trial of Ozempic (semaglutide) for the treatment of patients with type 2 diabetes.

Novo Nordisk has reported positive results from the SUSTAIN 6 trial, a Phase llla trial of Ozempic (semaglutide) for the treatment of patients with type 2 diabetes.

SUSTAIN 6 is part of the global SUSTAIN clinical development programme for Ozempic, which features eight Phase llla trials.

The SUSTAIN programme has enrolled more than 8,000 adults with type 2 diabetes, including some patients with high-cardiovascular risk profiles.

The SUSTAIN 6 trial enrolled 3,297 people with type 2 diabetes and established cardiovascular disease or with at least one cardiovascular risk factor.

It was conducted to analyse the non-inferiority of Ozempic in comparison with placebo, when administered along with standard of care.

“Cardiovascular disease remains the leading cause of disability and death in people with type 2 diabetes and there is an increasing focus on reducing cardiovascular risk in the clinic.”

The newly presented results, which are based on two post-hoc subgroup analyses of the SUSTAIN 6 trial, have showed Ozempic’s consistency in lowering the risk of major adverse cardiovascular events (MACE) in the patients who are at high-cardiovascular risk irrespective of their profile at the beginning of the trial.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The results showed that Ozempic-treated patients witnessed a 26% less risk of MACE versus those receiving placebo over a period of two years.

Swansea University UK School of Medicine professor Stephen Bain said: “Cardiovascular disease remains the leading cause of disability and death in people with type 2 diabetes and there is an increasing focus on reducing cardiovascular risk in the clinic.

“We have seen from clinical trials that diabetes treatments confer variable effects on cardiovascular outcomes and the results of these post-hoc analyses provide further evidence of the consistent cardiovascular risk reduction of Ozempic in people with type 2 diabetes, with varying profiles of cardiovascular risk at baseline.”

Ozempic is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) formulated for the treatment of adults with insufficiently controlled type 2 diabetes.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU